Markets
Pentagon Testosterone Screening Plan Sparks Medical Backlash — What It Means for Defense Health and Biotech Stocks
A growing coalition of physicians is publicly questioning the scientific foundation behind the Pentagon's proposed mandatory testosterone screening program, raising regulatory and commercial questions that ripple directly into defense health contracts and the diagnostics sector.